Durham, North Carolina, U.S., September 24, 2026
Clywedog Therapeutics has announced final results from its Phase 1b clinical study of balomenib in patients with Type 2 diabetes, reporting improvements in glycemic control that remained measurable for up to three months after participants completed a three-week course of treatment. The findings provide additional clinical data on balomenib, an investigational small-molecule therapy being developed by Clywedog Therapeutics as a potential treatment approach for Type 2 diabetes and metabolic disease. According to the company, the Phase 1b study evaluated the safety, tolerability and pharmacodynamic effects of balomenib in adults with Type 2 diabetes. The reported persistence of glycemic improvement after treatment was discontinued is a key finding from the study and supports continued investigation of the compound’s biological activity. The company said the results contribute to its ongoing development program as it evaluates balomenib’s potential to provide sustained metabolic benefits beyond the period of active dosing.
Phase 1b Study Evaluates Balomenib in Type 2 Diabetes
The Phase 1b study was designed to evaluate balomenib in adults living with Type 2 diabetes, with researchers assessing safety, tolerability and changes in measures of glycemic control. Early-stage clinical studies such as Phase 1b trials are generally designed to characterize an investigational therapy in humans and generate information that can guide later-stage development. In the Clywedog study, participants received a three-week course of balomenib, after which investigators continued to follow their metabolic outcomes. The company’s final analysis reported that improvements in glycemic measures persisted for approximately three months after completion of treatment. This observation provides additional information about the duration of balomenib’s effects and will be relevant as the company evaluates dosing strategies and the potential clinical development pathway for the therapy.
Glycemic Improvement Continued After Treatment
A central finding reported by Clywedog Therapeutics was the sustained improvement in glycemic control following the three-week treatment period. Rather than limiting assessments to the period during which patients were receiving balomenib, the study followed participants after treatment ended, allowing investigators to examine whether changes in metabolic measures persisted. The company reported that glycemic improvements remained evident for up to three months following the treatment course. Sustained effects after dosing has stopped can be important when evaluating investigational metabolic therapies because the duration of pharmacological effects can influence potential dosing schedules and overall treatment strategies. However, the Phase 1b findings remain clinical-development data, and additional studies will be necessary to determine the reproducibility, magnitude and clinical significance of the reported effects in larger patient populations.
Advertisement
Balomenib Advances Clywedog’s Clinical Program
The final Phase 1b results represent another milestone in Clywedog Therapeutics’ development of balomenib. The company is investigating the compound as part of its broader efforts to develop new therapeutic approaches for metabolic disorders. Type 2 diabetes is a chronic disease characterized by abnormal blood glucose regulation and often requires long-term treatment through lifestyle interventions, oral medicines, injectable therapies or combinations of approaches. New mechanisms that could provide durable improvements in glycemic control remain an active area of pharmaceutical research. Clywedog’s findings provide early clinical evidence that balomenib may influence glucose regulation beyond the active treatment period, although further clinical research will be required to establish its safety and efficacy.
The final Phase 1b analysis marks an important step in the clinical development of balomenib for Type 2 diabetes. The reported persistence of glycemic improvement for three months following a three-week treatment course distinguishes the findings from studies focused solely on responses during active dosing. As an investigational therapy, balomenib will require additional clinical evaluation to determine its long-term safety, efficacy, appropriate dosing and potential therapeutic role. The results nevertheless add to the growing body of research into innovative approaches for metabolic disease and provide Clywedog Therapeutics with additional clinical data to inform the next stages of its development program.
Source: Clywedog Therapeutics press release
